Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, Naoki K, Kobayashi N, Shukuya T, Shimokawa T, Ishihara M, Wakui H, Hosomi Y, Tanaka H, Saito H, Hosokawa S, Takiguchi Y, Kasai T, Nokihara H, Morita R, Aono H, Furuya N, Okamoto H. Nakamichi S, et al. Among authors: naoki k. Clin Lung Cancer. 2024 Jan;25(1):85-90. doi: 10.1016/j.cllc.2023.09.006. Epub 2023 Oct 4. Clin Lung Cancer. 2024. PMID: 37981477 Clinical Trial.
Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: naoki k. Br J Cancer. 2023 Dec;129(12):2034. doi: 10.1038/s41416-023-02481-x. Br J Cancer. 2023. PMID: 37923915 Free article. No abstract available.
Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy.
Torasawa M, Horinouchi H, Nomura S, Igawa S, Asai M, Ishii H, Wakui H, Ushio R, Asao T, Namba Y, Koyama R, Hayakawa D, Katayama I, Matsuda H, Sasaki S, Takahashi K, Hosomi Y, Naoki K, Ohe Y. Torasawa M, et al. Among authors: naoki k. J Thorac Oncol. 2024 Feb;19(2):325-336. doi: 10.1016/j.jtho.2023.09.1446. Epub 2023 Sep 23. J Thorac Oncol. 2024. PMID: 37748690 Free article.
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y. Shirasawa M, et al. Among authors: naoki k. Br J Cancer. 2023 Dec;129(12):2003-2013. doi: 10.1038/s41416-023-02427-3. Epub 2023 Sep 20. Br J Cancer. 2023. PMID: 37731022
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
Wada T, Hibino M, Aono H, Kyoda S, Iwadate Y, Shishido E, Ikeda K, Kinoshita N, Matsuda Y, Otani S, Kameda R, Matoba K, Nonaka M, Maeda M, Kumagai Y, Ako J, Shichiri M, Naoki K, Katagiri M, Takaso M, Iwamura M, Katayama K, Miyatsuka T, Orihashi Y, Yamaoka K; CORVETTE-01 Study Group. Wada T, et al. Among authors: naoki k. Front Med (Lausanne). 2023 May 22;10:1139046. doi: 10.3389/fmed.2023.1139046. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37283627 Free PMC article.
Multicenter, single-arm phase II study of modified carboplatin/nab-paclitaxel in untreated performance status 2 patients with advanced non-small cell lung cancer: TORG1426.
Ichikawa Y, Seki N, Honda T, Sakugawa M, Hosokawa S, Bessho A, Agemi Y, Shimokawa T, Otani S, Nakahara Y, Naoki K, Yomota M, Hosomi Y, Takiguchi Y, Tokito T, Ando S, Okamoto H. Ichikawa Y, et al. Among authors: naoki k. Transl Cancer Res. 2023 Apr 28;12(4):873-886. doi: 10.21037/tcr-22-2144. Epub 2023 Mar 23. Transl Cancer Res. 2023. PMID: 37180670 Free PMC article.
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Akazawa Y, Igawa S, Yamada K, Yamamoto H, Yagami Y, Kaizuka N, Manaka H, Kasajima M, Nakahara Y, Sato T, Mitsufuji H, Yokoba M, Kubota M, Sasaki J, Naoki K. Akazawa Y, et al. Among authors: naoki k. Oncology. 2023;101(11):685-694. doi: 10.1159/000530809. Epub 2023 Apr 25. Oncology. 2023. PMID: 37166346 Free PMC article.
169 results